|
27 Apr 2023 |
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
|
|
27 Apr 2023 |
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
|
|
26 Apr 2023 |
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
|
|
25 Apr 2023 |
Lilly to Divest BAQSIMI to Amphastar
|
|
25 Apr 2023 |
3B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology
|
|
20 Apr 2023 |
Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
|
|
20 Apr 2023 |
Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity
|
|
18 Apr 2023 |
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
|
|
18 Apr 2023 |
Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting
|
|
18 Apr 2023 |
Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline
|
|
14 Apr 2023 |
Guard Therapeutics closes its phase 2 clinical trial AKITA following DMC recommendation
|
|
13 Apr 2023 |
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives
|
|
11 Apr 2023 |
Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera
|
|
05 Apr 2023 |
Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors
|
|
04 Apr 2023 |
Orbit Discovery and Evergreen Discovery Collaborate to Discover Peptides for Targeting Radiopharmaceuticals
|
|
01 Apr 2023 |
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
|
|
28 Mar 2023 |
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
|
|
27 Mar 2023 |
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
|
|
27 Mar 2023 |
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
|
|
25 Mar 2023 |
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial
|
|
23 Mar 2023 |
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
|
|
22 Mar 2023 |
Debiopharm announces launch of the phase 1/2 GaLuCi™ study for its CA IX-targeted radiopharmaceutical program
|
|
22 Mar 2023 |
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
|
|
21 Mar 2023 |
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
|
|
21 Mar 2023 |
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout
|
